Clinical TopicsWeb Exclusives
fda treatment eosinophilic granulomatosis polyangiitis autoimmune disease vasculitis therapy approve stamp

FDA approves new treatment for eosinophilic granulomatosis with polyangiitis


On Dec. 12, the U.S. Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis. This new indication if the first FDA-approved therapy for EGPA.

Read more via

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.


Recent Posts